Labcorp Biopharma Laboratory Services: Antibody-drug conjugate (ADC) capabilities

Antibody-drug conjugates (ADCs) continue to be a widely used and key modality of interest for the pharmaceutical industry due to their ability to deliver targeted cytotoxic payloads to solid tumors and blood-based malignancies that induce cell apoptosis for oncology patients. While payload types continue to evolve beyond tubulin inhibitors and DNA-damaging agents, ADCs remain challenging given their highly complex and nuanced chemistry. For an ADC to be successful, the right combination of target-antigen, active linker payload, appropriate drug-to-antibody ratio (DAR), proper tumor indication, and payload conjugation site need to be considered.